Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Covington
Moodys
Federal Trade Commission
Cipla
Teva
AstraZeneca
Chubb
Farmers Insurance

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020702

« Back to Dashboard

NDA 020702 describes LIPITOR, which is a drug marketed by Pfizer and is included in one NDA. It is available from fourteen suppliers. Additional details are available on the LIPITOR profile page.

The generic ingredient in LIPITOR is atorvastatin calcium. There are sixty-one drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.
Summary for 020702
Tradename:LIPITOR
Applicant:Pfizer
Ingredient:atorvastatin calcium
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020702
Medical Subject Heading (MeSH) Categories for 020702
Suppliers and Packaging for NDA: 020702
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LIPITOR atorvastatin calcium TABLET;ORAL 020702 NDA Parke-Davis Div of Pfizer Inc 0071-0155 N 0071-0155-10
LIPITOR atorvastatin calcium TABLET;ORAL 020702 NDA Parke-Davis Div of Pfizer Inc 0071-0155 N 0071-0155-23

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:Dec 17, 1996TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Jun 23, 2020
Regulatory Exclusivity Use:CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 20MG BASE
Approval Date:Dec 17, 1996TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Jun 23, 2020
Regulatory Exclusivity Use:CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 40MG BASE
Approval Date:Dec 17, 1996TE:ABRLD:Yes

Expired US Patents for NDA 020702

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer LIPITOR atorvastatin calcium TABLET;ORAL 020702-001 Dec 17, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer LIPITOR atorvastatin calcium TABLET;ORAL 020702-004 Apr 7, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer LIPITOR atorvastatin calcium TABLET;ORAL 020702-003 Dec 17, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer LIPITOR atorvastatin calcium TABLET;ORAL 020702-004 Apr 7, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Federal Trade Commission
US Army
Julphar
Cantor Fitzgerald
Accenture
Covington
Cerilliant
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.